- • •
Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. Its principal activity consists of commercializing and distribution in Europe and the United States, Israel, and Australia of its drug candidate SCENESSE for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural α-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.